Jiangsu CoWin Biotech Co., Ltd. (SHA:688426)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Selling goods	114.94M				227.45M	197.83M	66.30M	-
Selling goods Growth	-				14.97%	198.41%	-	-
Services	78.48M				111.01M	35.38M	7.64M	3.15M
Services Growth	-				213.77%	362.87%	142.46%	-
Molecular Detection Products - Nucleic Acid Preservation Reagent	-				-	-	-	12.43M
Molecular Detection Products - Nucleic Acid Extraction and Purification Reagents	-				-	-	-	12.60M
Other	-				-	-	-	1.05M
Molecular Detection Products - Raw Enzymes and Detection Reagents	-				-	-	-	26.59M
Total	193.41M				338.46M	233.21M	73.94M	55.83M
Total Growth	-				45.13%	215.41%	32.44%	-

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
China	179.15M				290.69M	206.68M	72.82M	55.69M
China Growth	-				40.65%	183.83%	30.75%	-
Foreign	14.27M				47.78M	26.53M	1.12M	136.30K
Foreign Growth	-				80.06%	2268.70%	721.85%	-
Total	193.41M				338.46M	233.21M	73.94M	55.83M
Total Growth	-				45.13%	215.41%	32.44%	-

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 20, 2026

Data Sources Report a data error